Spine Market: Pure Plays Continue to Grab Share

Amidst low growth and a potential rebound in the $9 billion global spine market, the pure-play spine companies, including NuVasive, Globus, K2M and LDR, continue to outperform and grab share from the diversified giants. Medtech Insight founder and former CEO Sharon O'Reilly reports on these companies and more from the 2015 North American Spine Society (NASS) conference in Chicago, where the latest news centered around ancillary approaches to fusion, patient-specific tools, robotics, biologics, expandable cages, MIS and cervical discs.

Slow and stable growth is the new mantra for the spine market as the industry enters a mature stage – a welcome change from the turbulence experienced over the past few years. This year’s North American Spine Society (NASS) conference in Chicago was more subdued than past meetings and not rocked by major M&A or IPO announcements or new blockbuster products. (SeeAlso see "Orthopedics: Bracing For Change" - Medtech Insight, 29 May, 2015..) Instead, the buzz centered around ancillary approaches to fusion – the industry’s largest segment accounting for 88% of the total US spine hardware market according to BioMedGPS’ SmartTRAK Financial Dashboard as shown in Exhibit 1. Patient-specific tools, robotics, biologics, expandable cages and, not surprisingly, minimally invasive surgery and cervical discs were the dominant themes of the meeting. The general consensus based on conversations on the NASS 2015 exhibit floor is that the $9 billion global spine market will expand at a slow pace (about 2%), pricing will remain under pressure and the pure-play spine companies (NuVasive Inc., Globus Medical Inc., K2M Group Holdings Inc. and [LDR Spine USA Inc.]/LDR Holding Corp.) will continue to grab share from the diversified giants. (SeeAlso see "Spine Market: Making A Comeback" - Medtech Insight, 30 January, 2015..)

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Deals

Anglonordic 25: Women’s Health Needs Therapeutic Success To Encourage Wider Investment

 

Health tech is at the forefront of the women's health sector, securing 38% of venture capital in 2024. However, panelists at the Anglonordic Life Science Conference held 3 April asserted that a successful therapeutic breakthrough is key to gaining investor confidence and accelerating venture capital.

Careology And Entia Partner To ‘Enhance’ Remote Monitoring For Patients With Cancer

 

Careology and Entia are partnering to “alleviate the burden of routine patient assessments” on people with cancer. The two early-stage London-based health tech startups already provide services to UK National Health Service (NHS) patients.

Amplitude Acquisition Marks Global Medtech Entry With High Potential In India For Zydus

 
• By 

Zydus Lifesciences plans to expand global markets for patented products of French orthopedic tech company Amplitude Surgicals which it is acquiring from PE firm PAI Partners and others. Could the European business also serve as a buffer to upheaval in the US amid talks of tariffs?

US Federal Trade Commission Challenges Surmodics-Biocoat Merger Over Antitrust Concerns

 
• By 

A planned merger between medical device coating manufacturers Surmodics and Biocoat is facing an antitrust lawsuit from the US Federal Trade Commission. The FTC believes the move would create an illegal monopoly.

More from Business

Anglonordic 25: Women’s Health Needs Therapeutic Success To Encourage Wider Investment

 

Health tech is at the forefront of the women's health sector, securing 38% of venture capital in 2024. However, panelists at the Anglonordic Life Science Conference held 3 April asserted that a successful therapeutic breakthrough is key to gaining investor confidence and accelerating venture capital.

Enovis Appoints Damien McDonald CEO, Reaffirms Q1 Guidance Amid Strategic Growth Push

 
• By 

Enovis has named veteran medtech leader Damien McDonald as its new CEO effective 12 May as the orthopedic company reaffirms first-quarter 2025 revenue guidance of between $555m and $563m. Medtech Insight spoke with Tim Czartoski, Enovis’ president of US surgical and global product and enabling technologies, about the firm’s growth strategy and innovation plans.